Current Diabetes Reports

, Volume 4, Issue 6, pp 455–461 | Cite as

Diabetic nephropathy in African-American patients

  • Errol D. Crook
  • Sejal R. Patel
Article

Abstract

Diabetic nephropathy (DN) is the number one cause of endstage renal disease (ESRD) in the United States and is highly prevalent in African Americans. Since 1997, DN has been the number one cause of ESRD in African Americans. In African Americans, almost all DN is due to type 2 diabetes mellitus (T2DM), and nephropathy may affect female more than male patients. African Americans with T2DM are at increased risk for developing and having progression of DN. Glycemic control, development of albuminuria, family history of renal disease, and control of blood pressure are important risk factors for progression of DN. In addition, cigarette smoking, presence of hepatitis C, and use of thiazolinediones has an impact on renal survival in African Americans. Large vessel complications may be less frequent in African Americans with T2DM, when compared with white persons. Yet, cardiovascular disease and other microvascular complications are very common, and both are dependent on control of blood pressure. Achieving the recommended blood pressure of less than 130/80 mm Hg is essential but requires multiple antihypertensive medications, including an inhibitor of the renin-angiotensin system.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hsu C, Vittinghoff E, Lin F, Shilpak MG: The incidence of endstage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004, 141:95–101.PubMedGoogle Scholar
  2. 2.
    Crook ED: Diabetic renal disease in African Americans. Am J Med Sci 2002, 323:78–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Brancati FL, Whelton PK, Randall BL, et al.: Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997, 278:2069–2074.PubMedCrossRefGoogle Scholar
  4. 4.
    Brancati FL, Whittle JC, Whelton PK, et al.: The excess incidence of diabetic end-stage renal disease among blacks: a population-based study of potential explanatory factors. JAMA 1992, 268:3079–3084.PubMedCrossRefGoogle Scholar
  5. 5.
    Carter JS, Pugh JA, Monterrosa A: Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 1996, 125:221–232.PubMedGoogle Scholar
  6. 6.
    Powers DR, Wallin JD: End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Intern Med 1998, 158:793–800.PubMedCrossRefGoogle Scholar
  7. 7.
    Kramer HJ, Nguyen QD, Curhan G, Hsu CY: Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003, 289:3273–3277. Demonstrates high prevalence and heterogeneity of renal disease in patients with type 2 diabetes. Uses population-based data (NHANES III) so it is applicable to African-American patients.PubMedCrossRefGoogle Scholar
  8. 8.
    Young BA, Maynard C, Boyko EJ: Racial differences in diabetic nephropathy, cardiovascular disease and mortality in national population of veterans. Diabetes Care 2003, 26:2392–2399. Its large cohort size of greater than 400,000 (15.3% African American) makes this study one of the best for epidemiology of diabetes and its complications. It is limited by the fact that it is in veterans, making it an overwhelmingly male cohort, but the study looks at differences between ethnic groups.PubMedCrossRefGoogle Scholar
  9. 9.
    Krop JS, Coresh J, Chambless LE, et al.: A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs. whites with diabetes: the Atherosclerosis Risk in Communities study. Arch Intern Med 1999, 159:1777–1783.PubMedCrossRefGoogle Scholar
  10. 10.
    Crook ED, Harris J, Oliver B, et al.: Endstage renal disease due to diabetic nephropathy in Mississippi: an examination of factors influencing renal survival in a population prone to late referral. J Invest Med 2001, 49:284–291.Google Scholar
  11. 11.
    Brancati FL, Kao WH, Folsom AR, et al.: Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000, 283:2253–2259.PubMedCrossRefGoogle Scholar
  12. 12.
    Adeniyi A, Folsom AR, Brancati FL, et al.: Incidence and risk factors for cardiovascular disease in African Americans with diabetes: the atherosclerosis risk in communities (ARIC) study. J Natl Med Assoc 2002, 94:1025–1035. Specifically addresses CVD in African-American diabetic patients in a prospective, observational trial. Demonstrates that renal disease increases CVD risk.PubMedGoogle Scholar
  13. 13.
    Crook ED, Wofford P, Oliver B: Advanced diabetic nephropathy disproportionately affects African American females: cross-sectional analysis and determinants of renal survival in an academic renal clinic. Ethn Dis 2003, 13:28–33.PubMedGoogle Scholar
  14. 14.
    Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000, 11:155A.Google Scholar
  15. 15.
    Lebovitz HE, Palmisano J: Cross-sectional analysis of renal function in black Americans with NIDDM. Diabetes Care 1990, 13:1186–1190.PubMedCrossRefGoogle Scholar
  16. 16.
    Gambara V, Mecca G, Remuzzi G, et al.: Heterogeneous nature of renal lesions in type 2 diabetes. J Am Soc Nephrol 1993, 3:1458–1466.PubMedGoogle Scholar
  17. 17.
    Crook ED: Diabetic nephropathy in African Americans. Am J Hypertens 2001, 14:132S-138S.PubMedCrossRefGoogle Scholar
  18. 18.
    Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk. Is albumin excretion rate sufficient? Diabetes 2000, 49:1399–1408.PubMedCrossRefGoogle Scholar
  19. 19.
    Kohler KA, McClellan WM, Ziemer DC, et al.: Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. Am J Kidney Dis 2000, 36:903–913.PubMedGoogle Scholar
  20. 20.
    Goldschmid MG, Domin WS, Ziemer DC, et al.: Diabetes in urban African Americans. II. High prevalence of microalbuminuria and nephropathy in African-Americans with diabetes. Diabetes Care 1995, 18:955–961.PubMedCrossRefGoogle Scholar
  21. 21.
    Thaler LM, El-Kebbi IM, Ziemer DC, et al.: High prevalence of albuminuria among African Americans with short duration of diabetes [letter]. Diabetes Care 1998, 21:1576–1577.PubMedCrossRefGoogle Scholar
  22. 22.
    Ravid M, Borsh D, Ravid-Safran D, et al.: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 2001, 158:998–1004.CrossRefGoogle Scholar
  23. 23.
    Geiss LS, Rolka DB, Engelgau MM: Elevated blood pressure among U.S. adults with diabetes, 1988–1994. Am J Prev Med 2002, 22:42–48.PubMedCrossRefGoogle Scholar
  24. 24.
    Crook ED, Velusamy L: Are low blood pressure goals justified in persons with diabetes mellitus? Curr Hypertens Rep 2003, 5:231–238.PubMedGoogle Scholar
  25. 25.
    Young BA, Maynard C, Reiber G, Boyke EJ: Effects of ethnicity and nephropathy on lower extremity amputation risk among diabetic veterans. Diabetes Care 2003, 26:495–501.PubMedCrossRefGoogle Scholar
  26. 26.
    Tierney WM, McDonald CJ, Luft FC: Renal disease in hypertensive adults: effect of race and type II diabetes mellitus. Am J Kidney Dis 1989, 13:485–493.PubMedGoogle Scholar
  27. 27.
    Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330:877–884.PubMedCrossRefGoogle Scholar
  28. 28.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.Google Scholar
  29. 29.
    Breyer JA, Bain RP, Evans JK, et al.: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996, 50:1651–1658.PubMedCrossRefGoogle Scholar
  30. 30.
    Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group [no authors listed]. Lancet 1998, 352:837–853.Google Scholar
  31. 31.
    Patel S, Crook ED: Glycemic control predicts diabetic extrarenal complications but not renal survival [abstract]. Ethn Dis 2004, in press.Google Scholar
  32. 32.
    Seaquist ER, Goetz FC, Fich S, et al.: Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989, 320:1161–1165.PubMedCrossRefGoogle Scholar
  33. 33.
    Freedman BI, Tuttle AB, Spray BJ: Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1995, 25:710–713.PubMedGoogle Scholar
  34. 34.
    Fogarty DG, Rich SS, Hanna L, et al.: Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. Kidney Int 5 2000, 7:250–257.CrossRefGoogle Scholar
  35. 35.
    Satko SG, Langefeld CD, Daeihagh P, et al.: Nephropathy in siblings of African Americans with overt type 2 diabetic nephropathy. Am J Kidney Dis 2002, 40:489–494.PubMedCrossRefGoogle Scholar
  36. 36.
    Jacobsen P, Rossing K, Rossing P, et al.: Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998, 53:1002–1006.PubMedCrossRefGoogle Scholar
  37. 37.
    Crook ED, Genous L, Oliver B: Angiotensin converting enzyme genotype in Blacks with diabetic nephropathy: effects on risk of diabetes and its complications. J Invest Med 2003, 51:360–365.Google Scholar
  38. 38.
    Zhang H, Jia Y, Cooper JJ, et al.: Common variants in glutamine:fructose-6-phosphate aminotransferase 2 (GFPT2) gene are associated with type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels. J Clin Endocrinol Metab 2004, 89:748–755. Examines the relationship of a variation of a gene involved in glucose metabolism to nephropathy specifically in African-American patients.PubMedCrossRefGoogle Scholar
  39. 39.
    Singh LP, Andy J, Anyamele V, et al.: Hexosamine-induced fibronectin synthesis in mesangial cells is associated with increases in CREB phosphorylation and nuclear CRE-binding: the involvement of protein kinase A and C. Diabetes 2001, 50:2355–2362.PubMedCrossRefGoogle Scholar
  40. 40.
    Chuahirun T, Simoni J, Hudson C: Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci 2004, 327:57–67.PubMedCrossRefGoogle Scholar
  41. 41.
    Negrecha N, Crook ED: Cigarette smoking is a predictor or poorer renal survival in diabetic patients [abstract]. Am J Kidney Dis 2004, 43:A34.CrossRefGoogle Scholar
  42. 42.
    Penumalee S, Crook ED: Hepatitis C is a predictor of poorer renal survival in diabetic patients [abstract]. J Invest Med 2004, 52:S391.Google Scholar
  43. 43.
    Goyal A, Crook ED: Thiazolinediones and progression of renal disease in diabetic patients [abstract]. Ethn Dis 2004, in press.Google Scholar
  44. 44.
    Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 19:2560–2572. Most recent guidelines for treatment of blood pressure. Recommends RAS inhibitors in diabetic patients and a target blood pressure of less than 130/80 mm Hg.CrossRefGoogle Scholar
  45. 45.
    Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet 2003, 362:1527–1535.CrossRefGoogle Scholar
  46. 46.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997. This is the largest hypertension trial ever performed. Because African-American patients and diabetic patients made up a large part of the cohort, these results are pertinent to the topic of this paper. Important messages are that multiple medicines are required to reach blood pressure targets and that a thiazide-like diuretic was equal to an ACE inhibitor and calcium antagonists for CVD and renal outcomes.CrossRefGoogle Scholar
  47. 47.
    Crook ED, Preddie D: Relative effects of angiotensin converting enzyme inhibitors and calcium antagonists in advanced diabetic nephropathy. Ethn Dis 2004, 14:87–93.PubMedGoogle Scholar
  48. 48.
    Mokwe E, Ohmit SE, Nasser SA, et al.: Determinants of blood pressure response to quinapril in black and white hypertensive patients. The Quinapril Titration Interval Management Evaluation Trial. Hypertension 2004, 43:1202–1207.PubMedCrossRefGoogle Scholar
  49. 49.
    Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000, 160:685–693.PubMedCrossRefGoogle Scholar
  50. 50.
    Crook, ED, Harris J, Oliver B, et al.: The effect of enalapril on advanced diabetic nephropathy in African American females. Ethn Dis 2001, 11:211–216.PubMedGoogle Scholar
  51. 51.
    Brenner BM, Cooper ME, De Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869. Results from this trial led to US FDA approval of losartan for prevention of ESRD in diabetic patients with type 2 nephropathy. The proportion of African-American patients in this international trial was similar to that in the US population.PubMedCrossRefGoogle Scholar
  52. 52.
    Lewis EJ, Lawrence HG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860. Results from this trial led to US FDA approval of irbesartan for slowing of progression of renal disease in type 2 nephropathy. This international trial had a very small proportion of African-American patients.PubMedCrossRefGoogle Scholar
  53. 53.
    White O, Crook ED: Decreasing renal function is associated with incident cardiovascular disease in diabetics [abstract]. Ethn Dis 2004, in press.Google Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Errol D. Crook
    • 1
  • Sejal R. Patel
  1. 1.University Health ClinicWayne State University School of MedicineDetroitUSA

Personalised recommendations